A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
NCT06668103
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small Cell Lung Cancer With EGFR Mutation
Interventions
DRUG:
ABSK043 in combination with Firmonertinib
Sponsor
Abbisko Therapeutics Co, Ltd